These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18973733)

  • 1. The treatment of psoriatic arthritis and inflammatory spondylitis.
    Castro-Rueda H; Kavanaugh A
    Curr Pain Headache Rep; 2008 Dec; 12(6):412-7. PubMed ID: 18973733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.
    Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P
    Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
    Braun J; van der Heijde D
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1097-109. PubMed ID: 12831346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of psoriatic arthritis.
    Balakrishnan C; Madnani N
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment and treatment of psoriatic spondylitis.
    Nash P
    Curr Rheumatol Rep; 2009 Aug; 11(4):278-83. PubMed ID: 19691931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept (Enbrel) -- an update.
    Goffe B
    Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 11. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M; Favalli EG
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
    Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 16. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
    Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
    J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
    Saad AA; Hyrich KL; Ashcroft DM
    Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
    Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
    J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
    Soriano ER
    Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast for the treatment of psoriatic arthritis.
    Martin BC; Thomas LW; Dann FJ
    Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.